OPKO Health二季度业绩会重申上调2026年收入指引并推进MDX3001临床计划

Earnings Call Insights: OPKO Health (OPK) Q2 2026
Management View
- "During the second quarter, we made meaningful progress in improving operating efficiency and profitability and in advancing our product pipeline," said Dr. Phillip Frost (Chairman of the Board & CEO), while adding, "ModeX continues to move forward with its present portfolio of five clinical trial programs" and that OPKO "initiated a Phase I/IIa clinical safety and efficacy study in the U.S. of our GLP-1 glucagon candidate" with plans "to enroll 44 healthy volunteers and presumed MASH patients."
- Dr. Elias Zerhouni (President & Vice Chairman of the Board) said ModeX "expect[s] a sixth program, our in vivo CAR-T asset to begin first-in-human clinical trials by the end of this year or in early 2027," and described MDX2301 as "fully funded by BARDA" with the company "completing enrollment of its Phase I clinical trials in the third quarter of this year."
- Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) said OPKO ended Q2 "with over $300 million in cash, cash equivalents and restricted cash" and that "during the quarter, we repurchased 9.7 million shares for approximately $13 million" with "approximately $94 million authorized" remaining.
Outlook
- Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) guided Q3 2026 revenue to "$131 million to $142 million" and said the company expects "total costs and expenses for Q3" of "$180 million to $190 million" with "investments in R&D" of "$34 million and $38 million" (partially offset by "$5 million to $7 million" in BARDA and other collaboration funding).
- Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) said, "we're adjusting our full year guidance" and now expects 2026 total revenue of "$560 million and $585 million," alongside "total cost and expenses" of "$710 million to $740 million" (excluding "any future onetime items") and depreciation and amortization of "approximately $95 million."
- Relative to Q1 2026 framing, the company moved from affirming prior full-year guidance to an explicit update, with Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) stating in Q2, "we now expect an increase to our previously issued guidance" for total revenue and "reduced our total cost and expenses."
Financial Results
- Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) reported Q2 2026 consolidated "total revenues" of "$163.6 million" and a "net loss" of "$8.4 million or $0.01 per share," noting the prior-year quarter included "a $91.7 million of expense related to the exchange of our convertible notes."
- In Diagnostics, Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) reported Q2 2026 revenue of "$74.5 million, including $6.2 million from our 4Kscore Test" and said diagnostic operating income was "$4.8 million"; he also cited "an $18.1 million gain" tied to the final Labcorp earn-out payment that "offset operating expenses."
- In Pharmaceuticals, Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) reported revenue of "$89 million" and said R&D spending was "$32.7 million"; he also cited "$29.4 million in revenue recognized from Series A-2 preferred shares" received via the Nicoya partnership for Greater China RAYALDEE, and stated Pfizer gross profit share was "$6.4 million."
Q&A
- Sarah (for Brian Cheng), JPMorgan: Asked about first MDX3001 (in vivo CAR-T) indication and collaboration approach, and what OPKO needs to see to expand OPK-88006 in MASH; Dr. Elias Zerhouni (President & Vice Chairman of the Board) said the OPK-88006 goal is "showing that this molecule has a competitive profile" and to assess changes over 16 weeks using "fatty liver" measures and "biomarkers"; Dr. Gary Nabel (Chief Innovation Officer & Director) said for MDX3001 "our initial thought is that we would pursue studies in autoimmune disease" targeting B-cell depletion and that OPKO is "actively looking to partner with big pharma."
- Edward Tenthoff, Piper Sandler: Asked about MDX2001 enrollment pace, indication focus, and total Phase I size; Dr. Gary Nabel (Chief Innovation Officer & Director) said, "to date, we've enrolled 39 patients" and that OPKO is narrowing tumor types, adding, "I think that non-small cell lung cancer would be very high on that list," while total additional enrollment is "more likely it's going to be in the 10s."
- Kevin DeGeeter, Ladenburg Thalmann: Asked MDX2003 timing and prioritization of oncology vs. autoimmune; Dr. Gary Nabel (Chief Innovation Officer & Director) said "oncology first, autoimmune disease, second" and described initial focus in "B-cell lymphomas" to obtain safety and dose guidance.
- Yale Jen, Laidlaw: Asked OPK-88006 fibrosis stage targeting and mono vs. combo strategy; Dr. Elias Zerhouni (President & Vice Chairman of the Board) said OPKO is "definitely looking at F2 F3 to start" and later added, "we think there is a synergy, but it's a synergy within the molecule" via glucagon-driven increases in FGF21.
- Michael Petusky, Barrington: Asked timing for 4Kscore upside and cost-reduction sources; Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) said primary-care expansion is constrained because "we're still pending" Medicare-related confirmation and expects broader impact "more of a 2027 and beyond impact"; he added the guidance cost reduction was "mostly tied to the earn-out payment" gain.
- Yi Chen, H.C. Wainwright: Asked about diagnostics softness and OPK8801001 implications; Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) attributed the service-revenue guide adjustment to lines of business that are "taking a little longer to mature" and said 4Kscore is "slightly behind our expectations" due to a decision that "hasn't come through yet"; Dr. Zerhouni said OPK8801001 enables "once a week" dosing and that "it is more efficacious."
Sentiment Analysis
- Slightly negative (analysts): Questions repeatedly pressed on timing uncertainty and gating items, including reimbursement dependencies ("pending" Medicare confirmations) and enrollment/data timing (MDX2001 data perceived as pushed out).
- Slightly positive (management): Prepared remarks emphasized momentum and funding support, including Dr. Zerhouni’s "expect" language for MDX3001 clinic entry and Adam Logal’s "more than sufficient to fund" operations; in Q&A, management used cautionary timing language on reimbursement ("we're going to be cautious") while maintaining program ambition ("actively looking to partner with big pharma").
- Versus Q1 2026, management retained a similar catalyst-focused tone on ModeX, while Q2 added more explicit near-term constraints on 4Kscore expansion timing ("more of a 2027 and beyond impact") compared with Q1’s expectation that Medicare updates could happen "in the middle of this year."
Quarter-over-quarter comparison
- Guidance language shifted from Q1’s "affirming our full year guidance" to Q2’s explicit revision: "increase to our previously issued guidance" for total revenue and "reduced" cost expectations.
- Diagnostics narrative moved from Q1’s expectation to reach breakeven "by the middle of the year" to Q2’s statement that the company anticipates achieving profitability objectives "in 2026," while noting Q2 "operational headwinds" that created "slightly higher costs."
- Pipeline emphasis remained consistent (ModeX five clinical assets plus in vivo CAR-T), while Q2 added concrete MDX2001 enrollment disclosure ("39 patients") and a clearer MDX3001 partnering push ("actively looking to partner with big pharma").
Risks and Concerns
- Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) cited Diagnostics cost pressure from "operational headwinds" and said 4Kscore expansion is constrained until CMS-related changes are confirmed; he said the company will remain "cautious in the primary care space" until that occurs.
- Dr. Zerhouni (President & Vice Chairman of the Board) flagged MASH trial recruitment friction, stating, "the recruitment of these studies can be challenged because there's a tremendous amount of studies going on," and said OPKO will focus on F2/F3 because it is "easier to enroll."
Final Takeaway
Management framed Q2 as a step toward improved operating performance while keeping R&D intensity elevated, pairing a pipeline-heavy update (including a planned MDX3001 first-in-human start by end of 2026 or early 2027 and multiple ModeX readouts) with a revised 2026 outlook of $560 million to $585 million in revenue and $710 million to $740 million in costs. In Diagnostics, leadership pointed to progress toward profitability but tied meaningful 4Kscore acceleration to unresolved Medicare policy confirmation, which management said is more likely to affect results in 2027 and beyond.
Read the full Earnings Call Transcript